How to Get Trulicity (Dulaglutide) in Indiana

Who Prescribes Trulicity in Indiana

Any Indiana-licensed prescriber with appropriate authority can write a Trulicity prescription. That includes physicians (MDs and DOs), nurse practitioners, and physician assistants. Indiana grants full prescriptive authority to NPs who hold a collaborative practice agreement, per Indiana Code IC 25-23-1, and PAs prescribe under physician supervision per state medical board rules.

Your prescriber does not need to be an endocrinologist. Primary care physicians write the majority of GLP-1 prescriptions nationally. A 2023 analysis published in Diabetes Care found that primary care clinicians initiated 68% of new GLP-1 receptor agonist prescriptions in commercially insured adults with type 2 diabetes [1]. If you already have a primary care provider in Indiana who manages your diabetes, that visit is often the fastest path to a prescription.

The prescriber will evaluate your A1C history, current medications, BMI, and cardiovascular risk before deciding whether dulaglutide is appropriate. Trulicity's FDA-approved labeling specifies its indication for adults with type 2 diabetes as an adjunct to diet and exercise [2].

Telehealth Access to Trulicity in Indiana

Indiana law permits telehealth prescribing of Trulicity. The state's telehealth parity statute (IC 25-1-9.5) allows licensed providers to evaluate patients, establish care, and prescribe medications through synchronous audio-video visits. Dulaglutide is not a controlled substance, which removes the DEA-related barriers that restrict some telehealth prescriptions.

Several telehealth platforms operate in Indiana and can prescribe GLP-1 receptor agonists. A typical telehealth workflow looks like this: you complete an intake form, upload recent lab work (or get orders for new labs), attend a video consultation, and receive an electronic prescription sent directly to your pharmacy. Most platforms can complete this process within 3 to 7 business days.

The American Telemedicine Association notes that "telehealth visits for chronic disease management, including diabetes, produce clinical outcomes comparable to in-person care when patients have access to appropriate monitoring tools" [3]. For Indiana patients in rural counties without a nearby endocrinologist, telehealth may be the most practical route. Indiana has 92 counties, and according to the Health Resources and Services Administration, 71 of them contain at least one primary care health professional shortage area [4].

Labs Required Before Starting Trulicity

Prescribers in Indiana will order baseline labs before initiating dulaglutide. These are not optional. They confirm the diagnosis, rule out contraindications, and establish a monitoring baseline.

Standard pre-Trulicity lab panel:

• HbA1c (must confirm type 2 diabetes diagnosis, typically A1C ≥ 6.5%)
• Fasting glucose or oral glucose tolerance test
• Comprehensive metabolic panel (kidney function via eGFR, liver enzymes, electrolytes)
• Lipid panel (LDL, HDL, triglycerides)
• Thyroid function (TSH, free T4)

Thyroid screening is particularly relevant because GLP-1 receptor agonists carry an FDA boxed warning about medullary thyroid carcinoma risk observed in rodent studies [2]. Dulaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [5].

The American Diabetes Association's Standards of Care 2024 recommends A1C testing at least twice yearly for patients meeting treatment goals and quarterly for those whose therapy has changed or who are not meeting glycemic targets [6]. Your Indiana prescriber will likely recheck A1C at 12 weeks after starting Trulicity.

Indiana Medicaid and Insurance Coverage

This is the single biggest barrier for many Indiana patients. Indiana Medicaid does not cover Trulicity for type 2 diabetes. Patients enrolled in the Healthy Indiana Plan (HIP) or traditional Medicaid will need to explore alternatives or appeal through an exceptions process.

For commercially insured patients, coverage varies by plan. Most commercial insurers will cover Trulicity, but prior authorization is required in nearly every case. A 2022 survey by the American Medical Association found that 94% of physicians reported that prior authorization led to care delays, and 33% reported that prior authorization led to a serious adverse event for a patient in their practice [7].

What prior authorization requires in Indiana:

• Documented A1C ≥ 7.0% (or ≥ 6.5% with comorbidities, depending on the plan)
• Proof of metformin trial (usually 90 days) or documented metformin intolerance
• Diagnosis code for type 2 diabetes (ICD-10: E11.xx)
• Prescriber's clinical rationale for GLP-1 therapy

If your commercial plan denies coverage, your prescriber can file a peer-to-peer review. Eli Lilly also offers the Trulicity Savings Card, which may reduce co-pays to as low as $25 per month for eligible commercially insured patients. Uninsured patients may qualify for the Lilly Insulin Value Program or patient assistance programs, though eligibility criteria apply.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has stated: "Cost and access barriers to evidence-based diabetes medications remain one of the most significant obstacles to improving outcomes in the United States" [8].

Pharmacy Options and 503A Compounding

Indiana patients can fill Trulicity prescriptions at any licensed retail pharmacy. Major chains (CVS, Walgreens, Kroger) and independent pharmacies across the state stock brand-name Trulicity. Specialty pharmacies may offer additional support services like cold-chain shipping and injection training.

Indiana also permits access through 503A compounding pharmacies. A 503A pharmacy operates under a patient-specific prescription and can compound dulaglutide if the prescriber determines that a commercially available formulation does not meet the patient's needs (for example, a dose not available in the standard prefilled pen). However, 503A-compounded dulaglutide is not the same as FDA-approved Trulicity. The FDA's guidance on compounding specifies that 503A pharmacies must compound in response to individual prescriptions and cannot produce large batches for general distribution [9].

Retail pricing without insurance for brand-name Trulicity averages $950 to $1,100 for a 30-day supply (four prefilled pens at the maintenance dose). GoodRx and similar discount platforms sometimes reduce this to $800 to $900 at Indiana pharmacies. Compounded formulations through 503A pharmacies may cost less, but pricing varies by pharmacy and dose.

Dosing and What to Expect After Starting

Trulicity is initiated at 0.75 mg once weekly, injected subcutaneously in the abdomen, thigh, or upper arm. If glycemic response is insufficient after at least four weeks, the dose can increase to 1.5 mg weekly. The maximum approved dose is 4.5 mg weekly [2].

The AWARD-11 trial (N=1,842) compared the 3.0 mg and 4.5 mg doses against 1.5 mg and found that the 4.5 mg dose produced a mean A1C reduction of 1.87% from baseline at 36 weeks, compared to 1.64% for 1.5 mg [10]. Weight loss was also dose-dependent: 4.5 mg produced a mean reduction of 4.6 kg vs. 3.0 kg for 1.5 mg.

Common side effects during the first 2 to 4 weeks include nausea (affecting 12% to 21% of patients across clinical trials), diarrhea, vomiting, and decreased appetite [2]. These gastrointestinal effects tend to diminish with continued use. Starting at the lower 0.75 mg dose and titrating slowly helps reduce GI symptoms.

For most Indiana patients filling at a retail pharmacy, expect to receive the Trulicity pen within 1 to 5 business days of the prescription being processed. Specialty pharmacy fulfillment with cold-chain shipping typically takes 3 to 7 business days. Telehealth-to-doorstep timelines run approximately 5 to 10 business days including the initial consultation.

Cardiovascular Benefits: The REWIND Evidence

Trulicity is the only GLP-1 receptor agonist with cardiovascular outcome data from a population where 69% of participants did not have established cardiovascular disease at baseline. The REWIND trial (N=9,901) followed patients with type 2 diabetes for a median of 5.4 years and found that dulaglutide 1.5 mg reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 12% (HR 0.88 to 95% CI 0.79 to 0.99, P=0.026) [11].

This matters for prescribing decisions in Indiana. The ADA Standards of Care recommend a GLP-1 receptor agonist with proven cardiovascular benefit for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, or for those at high cardiovascular risk [6]. If you have coronary artery disease, a history of stroke, or peripheral artery disease, Trulicity carries this specific evidence-based advantage.

REWIND also showed a 15% reduction in the secondary renal composite endpoint (new macroalbuminuria, sustained decline in eGFR of ≥ 30%, or chronic renal replacement therapy) [11]. For Indiana patients with both type 2 diabetes and early-stage chronic kidney disease, this renal signal adds clinical rationale for choosing dulaglutide.

Transferring a Trulicity Prescription to Indiana

If you are moving to Indiana from another state, you can transfer an existing Trulicity prescription. Indiana accepts prescription transfers from all 50 states for non-controlled medications. Contact your current pharmacy and request the transfer to an Indiana pharmacy of your choice. The receiving pharmacist will verify the prescription with the originating pharmacy.

If your prescription has no remaining refills, your new Indiana provider will need to write a new one. Bring your most recent lab results, medication list, and prior authorization approval letter (if applicable) to your first appointment. This documentation speeds up the re-authorization process with your new insurer.

Patients relocating from states where they used telehealth platforms should confirm that the platform is also licensed to practice in Indiana. Not all telehealth services operate in every state. If your current platform does not serve Indiana, you will need to establish care with an Indiana-licensed provider.